DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program.



Post IPO Equity




Org chart

James E. Brown
President & CEO
Norman L. Sussman
Chief Medical Officer
Jian Li
SVP, Finance & Corporate Controller
Judy Joice
SVP, Operations & Corporate Quality Assurance
Andrew R. Miksztal
VP, Pharmaceutical Research & Development, Principal Scientist
David J. Ellis
VP, Clinical Development
Keith L. Lui
SVP, Business Development, Commercial, Medical Affairs
Steve Helmer
Vice President, Chief Patent Counsel
Weiqi Lin
EVP, Research & Development & Principal Scientist
Dorothy Engelking
VP, Regulatory Affairs
Two candidates
The Org
helps you hire
great candidates
It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.